Black Diamond Therapeutics (BDTX)
(Real Time Quote from BATS)
$5.38 USD
-0.09 (-1.65%)
Updated Jun 18, 2024 12:30 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Brokerage Reports
Black Diamond Therapeutics, Inc. [BDTX]
Reports for Purchase
Showing records 61 - 80 ( 88 total )
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
ASCO 2021 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Pushing Forward Through Diversity; Ph 1 Dataset Encouraging
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-189 Shows Improved Safety and Initial Anti-Tumor Activity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q1 Financials; First Look at BDTX-189 Ahead at ASCO
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Takeaways from 2021 AACR Virtual Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Competitive Landscape Updates from AACR; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
4Q20 Earnings; Preliminary BDTX-189 Data Expected 1H:2021
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Partial Clinical Hold Non-Impactful, In Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX Presents Preclinical Data for BRAF and FGFR 2/3 MasterKey Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Intriguing Preclinical BRAF and FGFR Programs Could Drive Upside to Our Valuation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biliary Cancer Data Further Supports Tumor Agnostic Strategy
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Initiating with an OUTPERFORM and $45 PT: Carving Through Cancer
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R